At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,463 enrolled
Drug / intervention
SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenaseother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The International Study of Inflammation in COVID-19: A Prospective Multi-Center Observational Study Examining the Role of Biomarkers of Inflammation in Predicting Covid-19 Related Outcomes in Hospitalized Patients
In Brief
An observational study evaluating SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase for Covid19 and 4 related conditions. Completed, enrolled 4,463 participants across 1 site.
Detailed Summary
This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation
CountriesUnited States
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
First PostedMar 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedMar 26, 2021
Enrollment StartFeb 1, 2020
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.3 years ago
Interventions
SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenaseother
Biomarkers of inflammation